Daniel Rob1, Rudolf Špunda2, Jaroslav Lindner2, Vilém Rohn3, Jan Kunstýř4, Martin Balík4, Jan Rulíšek4, Petr Kopecký4, Michal Lipš4, Ondřej Šmíd1, Tomáš Kovárník1, František Mlejnský2, Aleš Linhart1, Jan Bělohlávek1. 1. 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 2. 2nd Surgery Department - Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. 3. Cardiovascular Surgery Department, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. 4. Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Abstract
AIMS: Ventricular septal rupture (VSR) became a rare mechanical complication of myocardial infarction in the era of percutaneous coronary interventions but is associated with extreme mortality in patients who present with cardiogenic shock (CS). Promising outcomes have been reported with the use of circulatory support allowing haemodynamic stabilization, followed by delayed repair. Therefore, we analysed our experience with an early use of Veno-Arterial Extracorporeal Membrane Oxygenation (V-A ECMO) for postinfarction VSR. METHODS AND RESULTS: We conducted a retrospective search of institutional database for patients presenting with postinfarction VSR from January 2007 to June 2016. Data from 31 consecutive patients (mean age 69.5 ± 9.1 years) who were admitted to hospital were analysed. Seven out of 31 patients with VSR who were in refractory CS received V-A ECMO support preoperatively. ECMO improved end-organ perfusion with decreased lactate levels 24 hours after implantation (7.9 mmol/L vs. 1.6 mmol/L, p = 0.01), normalized arterial pH (7.25 vs. 7.40, p < 0.04), improved mean arterial pressure (64 mmHg vs. 83 mmHg, p < 0.01) and lowered heart rate (115/min vs. 68/min, p < 0.01). Mean duration of ECMO support was 12 days, 5 out of 7 patients underwent surgical repair, 4 were weaned from ECMO, 3 survived 30 days and 2 survived more than 1 year. The most frequent complication (5 patients) and the cause of death (3 patients) was bleeding. CONCLUSIONS: Our experience suggests that early V-A ECMO in patients with VSR and refractory CS might prevent irreversible multiorgan failure by improved end-organ perfusion. Bleeding complications remain an important limitation of this approach.
AIMS: Ventricular septal rupture (VSR) became a rare mechanical complication of myocardial infarction in the era of percutaneous coronary interventions but is associated with extreme mortality in patients who present with cardiogenic shock (CS). Promising outcomes have been reported with the use of circulatory support allowing haemodynamic stabilization, followed by delayed repair. Therefore, we analysed our experience with an early use of Veno-Arterial Extracorporeal Membrane Oxygenation (V-A ECMO) for postinfarction VSR. METHODS AND RESULTS: We conducted a retrospective search of institutional database for patients presenting with postinfarction VSR from January 2007 to June 2016. Data from 31 consecutive patients (mean age 69.5 ± 9.1 years) who were admitted to hospital were analysed. Seven out of 31 patients with VSR who were in refractory CS received V-A ECMO support preoperatively. ECMO improved end-organ perfusion with decreased lactate levels 24 hours after implantation (7.9 mmol/L vs. 1.6 mmol/L, p = 0.01), normalized arterial pH (7.25 vs. 7.40, p < 0.04), improved mean arterial pressure (64 mmHg vs. 83 mmHg, p < 0.01) and lowered heart rate (115/min vs. 68/min, p < 0.01). Mean duration of ECMO support was 12 days, 5 out of 7 patients underwent surgical repair, 4 were weaned from ECMO, 3 survived 30 days and 2 survived more than 1 year. The most frequent complication (5 patients) and the cause of death (3 patients) was bleeding. CONCLUSIONS: Our experience suggests that early V-A ECMO in patients with VSR and refractory CS might prevent irreversible multiorgan failure by improved end-organ perfusion. Bleeding complications remain an important limitation of this approach.
Authors: Anju Bhardwaj; Sachin Kumar; Ismael A Salas de Armas; Angelo Nascimbene; Sriram Nathan; Biswajit Kar; Igor D Gregoric Journal: Ann Cardiothorac Surg Date: 2022-05
Authors: Daniele Ronco; Matteo Matteucci; Mariusz Kowalewski; Michele De Bonis; Francesco Formica; Federica Jiritano; Dario Fina; Thierry Folliguet; Nikolaos Bonaros; Claudio Francesco Russo; Sandro Sponga; Igor Vendramin; Carlo De Vincentiis; Marco Ranucci; Piotr Suwalski; Giosuè Falcetta; Theodor Fischlein; Giovanni Troise; Emmanuel Villa; Guglielmo Actis Dato; Massimiliano Carrozzini; Giuseppe Filiberto Serraino; Shabir Hussain Shah; Roberto Scrofani; Antonio Fiore; Jurij Matija Kalisnik; Stefano D'Alessandro; Vittoria Lodo; Adam R Kowalówka; Marek A Deja; Salman Almobayedh; Giulio Massimi; Matthias Thielmann; Bart Meyns; Fareed A Khouqeer; Nawwar Al-Attar; Matteo Pozzi; Jean-François Obadia; Udo Boeken; Nikolaos Kalampokas; Carlo Fino; Caterina Simon; Shiho Naito; Cesare Beghi; Roberto Lorusso Journal: JAMA Netw Open Date: 2021-10-01
Authors: Abdulla A Damluji; Sean van Diepen; Jason N Katz; Venu Menon; Jacqueline E Tamis-Holland; Marie Bakitas; Mauricio G Cohen; Leora B Balsam; Joanna Chikwe Journal: Circulation Date: 2021-06-15 Impact factor: 39.918